Previous 10 | Next 10 |
Jasper Therapeutics press release ( NASDAQ: JSPR ): Q2 GAAP EPS of -$0.29 beats by $0.02 . Cash and cash equivalents as of June 30, 2022 were $60.8 million compared to $84.7 million as of December 31, 2021. The Company expects current cash and cash equivalents to b...
First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia On schedule to initiate a registrational study in AML in the first quarter of 2023 On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lo...
REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2 nd Annual Genetic Medicines Symposium...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Thursday! We’ve got earnings reports, public stock offerings, business agreement...
Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Te...
REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42 nd Annual Growth Stock Conference, to b...
REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. P...
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of the first patient in the Company’s sponsored research of the Center for Definitiv...
Jasper Therapeutics press release (NASDAQ:JSPR): Q1 GAAP EPS of -$0.06 beats by $0.29. The company expects current cash and cash equivalents of $70.4M to be sufficient to fund its planned operating and capital expenditures through early 2023. For further details see: Jasper Therapeutics...
Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023 Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients with MDS or AML presented at the 2022 Transplantation & Cellular Therapy (...
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
Jasper Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneou...
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
2024-06-16 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...